Mojca Jongen‐Lavrencic

6.8k total citations · 2 hit papers
69 papers, 3.1k citations indexed

About

Mojca Jongen‐Lavrencic is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Mojca Jongen‐Lavrencic has authored 69 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 25 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Mojca Jongen‐Lavrencic's work include Acute Myeloid Leukemia Research (39 papers), MicroRNA in disease regulation (12 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mojca Jongen‐Lavrencic is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), MicroRNA in disease regulation (12 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mojca Jongen‐Lavrencic collaborates with scholars based in Netherlands, United States and Germany. Mojca Jongen‐Lavrencic's co-authors include Bob Löwenberg, Su Ming Sun, Peter J.M. Valk, M K Dijkstra, Gert J. Ossenkoppele, Pieter Sonneveld, Bart J. Biemond, Marinus van Marwijk Kooy, Gerard Vreugdenhil and Johan Maertens and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Mojca Jongen‐Lavrencic

68 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. New England Journal of Medicine profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mojca Jongen‐Lavrencic Netherlands	28	1.7k	1.6k	850	560	447	69	3.1k
Karl S. Theil United States	27	2.3k 1.3×	1.2k 0.7×	279 0.3×	449 0.8×	798 1.8×	73	3.6k
Mar Tormo Spain	32	2.1k 1.2×	1.3k 0.8×	236 0.3×	646 1.2×	1.0k 2.3×	106	3.1k
Christopher S. Hourigan United States	28	1.6k 0.9×	814 0.5×	400 0.5×	444 0.8×	460 1.0×	106	2.5k
Válerie de Haas Netherlands	28	1.4k 0.8×	868 0.5×	353 0.4×	428 0.8×	1.1k 2.6×	99	2.5k
Claude Gardin France	35	3.2k 1.9×	1.9k 1.2×	229 0.3×	750 1.3×	800 1.8×	123	4.3k
MM Le Beau United States	31	1.9k 1.1×	1.3k 0.8×	261 0.3×	409 0.7×	760 1.7×	54	3.1k
Aref Al‐Kali United States	25	1.6k 1.0×	1.1k 0.7×	204 0.2×	278 0.5×	204 0.5×	210	2.5k
Carrie Fidler United Kingdom	28	1.1k 0.6×	972 0.6×	342 0.4×	268 0.5×	106 0.2×	61	2.8k
Toshiko Motoji Japan	26	1.5k 0.9×	915 0.6×	148 0.2×	578 1.0×	366 0.8×	121	2.6k
Stefan Hohaus Italy	39	1.5k 0.9×	1.4k 0.9×	430 0.5×	1.4k 2.4×	335 0.7×	167	4.2k

Countries citing papers authored by Mojca Jongen‐Lavrencic

Since Specialization

Citations

This map shows the geographic impact of Mojca Jongen‐Lavrencic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mojca Jongen‐Lavrencic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mojca Jongen‐Lavrencic more than expected).

Fields of papers citing papers by Mojca Jongen‐Lavrencic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mojca Jongen‐Lavrencic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mojca Jongen‐Lavrencic. The network helps show where Mojca Jongen‐Lavrencic may publish in the future.

Co-authorship network of co-authors of Mojca Jongen‐Lavrencic

This figure shows the co-authorship network connecting the top 25 collaborators of Mojca Jongen‐Lavrencic. A scholar is included among the top collaborators of Mojca Jongen‐Lavrencic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mojca Jongen‐Lavrencic. Mojca Jongen‐Lavrencic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jongen‐Lavrencic, Mojca, Thomas Pabst, Pierre Bories, et al.. (2024). MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study. Blood. 144(Supplement 1). 2881–2881. 4 indexed citations

Tahir, Stephen K., Emiliano Calvo, Benedito A. Carneiro, et al.. (2023). Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 141(17). 2114–2126. 9 indexed citations

Grob, Tim, Adil S. A. Al Hinai, Mathijs A. Sanders, et al.. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 139(15). 2347–2354. 159 indexed citations breakdown →

Jongen‐Lavrencic, Mojca, et al.. (2021). Non-Invasive Prenatal Testing Leading to Detection of Asymptomatic Acute Myeloid Leukemia in a 30-Year-Old Patient: A Case Report. Journal of Hematology. 10(5). 228–231. 1 indexed citations

Chiţu, Dana, Violaine Havelange, Mojca Jongen‐Lavrencic, et al.. (2017). Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15). Blood. 130. 463–463. 5 indexed citations

Dinmohamed, Avinash G., Otto Visser, Eduardus F. M. Posthuma, et al.. (2017). MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. Cancer Epidemiology. 50(Pt A). 137–140. 3 indexed citations

Hatzl, Stefan, Rotraud Wieser, Martin Pichler, et al.. (2016). Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research. 76(12). 3644–3654. 39 indexed citations

Dinmohamed, Avinash G., Otto Visser, Yvette van Norden, et al.. (2015). Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012. Leukemia. 30(1). 24–31. 54 indexed citations

Dinmohamed, Avinash G., Otto Visser, Yvette van Norden, et al.. (2014). Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. European Journal of Cancer. 50(5). 1004–1012. 41 indexed citations

10.

Song, Su Jung, Keisuke Ito, Ugo Ala, et al.. (2013). The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation. Cell stem cell. 13(1). 87–101. 257 indexed citations

11.

Blommestein, Hedwig M., et al.. (2012). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research. 37(3). 245–250. 34 indexed citations

12.

Sun, Su Ming, Veronika Ročková, Lars Bullinger, et al.. (2012). The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 27(1). 100–106. 48 indexed citations

13.

Löwenberg, Bob, Gert J. Ossenkoppele, Wim van Putten, et al.. (2009). High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. New England Journal of Medicine. 361(13). 1235–1248. 596 indexed citations breakdown →

14.

Corthals, Sophie L., Mojca Jongen‐Lavrencic, Yvonne de Knegt, et al.. (2009). Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leukemia Research. 34(5). 677–681. 52 indexed citations

15.

Wang, Mindy, Kirsten van Lom, G. Harms, et al.. (2008). miRNA analysis in B‐cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR‐150 and high BIC /miR‐155 expression. The Journal of Pathology. 215(1). 13–20. 92 indexed citations

16.

Jongen‐Lavrencic, Mojca, Stéphanie Salesse, Ruud Delwel, & Catherine M. Verfaillie. (2005). BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells. Leukemia. 19(3). 373–380. 27 indexed citations

17.

Peeters, Harald, Mojca Jongen‐Lavrencic, C Bakker, et al.. (1999). Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatology International. 18(5-6). 201–206. 33 indexed citations

18.

Avontuur, J.A., et al.. (1998). Effect of l-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNFα and nitrite/nitrate in human septic shock. Intensive Care Medicine. 24(7). 673–679. 27 indexed citations

19.

Stam, Tanja C., Mojca Jongen‐Lavrencic, A.M.M. Eggermont, & A. J. G. Swaak. (1996). Effects of isolated limb perfusion with tumour necrosis factor‐alpha on the function of monocytes and T lymphocytes in patients with cancer. European Journal of Clinical Investigation. 26(12). 1085–1091. 9 indexed citations

20.

Jongen‐Lavrencic, Mojca, Harald Peeters, Bianca Backx, et al.. (1994). R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatology International. 14(3). 109–113. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact